Opinion|Videos|September 2, 2024
IMbrave 150: Patient Characteristics
The panel analyzes how patient characteristics from the IMbrave 150 trial compare to those in other hepatocellular carcinoma studies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do the patient characteristics from IMbrave 150 compare to other trials that are being studied in HCC?
Advertisement
Related to this article
Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma.
Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.
SOHO 2026 sessions covered chemoimmunotherapy in frontline DLBCL, treatment selection via molecular classifiers, and bispecific antibodies for unfit patients.
The FDA cleared the Triton 1 robotic endoscopy system for diagnostic and therapeutic procedures such as colorectal cancer screening and lesion removal.
ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.
Investigators are evaluating cesalatamig among patients with advanced cancer in the international phase 1/2 BiPAVE-001 trial.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
Based on updated data from the TRUST-1 trial, a sNDA for taletrectinib has been approved by the FDA for patients with TKI-naive ROS1+ NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
2
FDA Clears Triton Robotic Endoscopy System for Colon Procedures
3
ASTRO Issues First Clinical Practice Guideline on Radiation for Bladder Cancer
4
KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors
5